Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1183MR)

This product GTTS-WQ1183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1183MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2364MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ1651MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ8662MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ483MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ5827MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ12610MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ1415MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ8387MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW